A fish in troubled waters: FDA weighs cancer risk of calcitonin salmon meds
This article was originally published in Scrip
Executive Summary
While Novartis and Unigene Laboratories, along with its US distribution partner Upsher Smith, would be wounded if the FDA decides to limit the use of calcitonin salmon medicines used to treat postmenopausal osteoporosis – or even force the drugs from the US market – companies in the midst of developing those products, like Tarsa Therapeutics, may ultimately suffer the greatest consequences.